Abstract Number: 536 • 2015 ACR/ARHP Annual Meeting
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By TNF-Alpha and IL-6 Axis in Accompany with Disease Activity in Rheumatoid Arthritis Patients
Background/Purpose: Recently, three different subsets of circulating monocytes: CD14brightCD16- (classical), CD14brightCD16+ (intermediate) and CD14dimCD16+ (nonclassical) monocytes have been defined. It has been reported that circulating…Abstract Number: 537 • 2015 ACR/ARHP Annual Meeting
The Course of Bone Marrow Edema in Early Undifferentiated and Rheumatoid Arthritis; A Longitudinal MRI Study on Bone Level
Background/Purpose: In rheumatoid arthritis (RA) patients, bone marrow edema (BME)-scores are associated with development of erosions. However, little is known on the course and outcome…Abstract Number: 538 • 2015 ACR/ARHP Annual Meeting
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
Background/Purpose: A large fraction of patients with RA does not respond to treatment with glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs), or becomes resistant in…Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…Abstract Number: 540 • 2015 ACR/ARHP Annual Meeting
Clinical Relevance of Etanercept Levels and Anti-Etanercept Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients
Background/Purpose: Biological compounds have belonged to the therapeutic options for the treatment of rheumatoid arthritis for about 15 years. The application of biological substances is…Abstract Number: 541 • 2015 ACR/ARHP Annual Meeting
Microrna-125b Expression in PBMCs Is Associated with Disease Activity in Patients with Early Rheumatoid Arthritis
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs that function as negative regulators of gene expression at posttranscription level and play a significant role in rheumatoid…Abstract Number: 542 • 2015 ACR/ARHP Annual Meeting
Reduced Expression of Mir-204 in Early RA Promotes Inflammatory Pathways in Synovial Fibroblasts
Background/Purpose: Synovial fibroblasts (SF) from the joints of RA patients display an activated and invasive phenotype. They produce a number of pro-inflammatory cytokines and proteolytic…Abstract Number: 543 • 2015 ACR/ARHP Annual Meeting
The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and bone erosions. Successful treatment can compromise…Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…Abstract Number: 545 • 2015 ACR/ARHP Annual Meeting
Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
Background/Purpose: Baseline sIL-2Rα levels predicted total mortality in both pre-RA and matched CN subjects, in a preceding prospective cohort study (A&R 2010; 62:S19). Now, the…Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…Abstract Number: 547 • 2015 ACR/ARHP Annual Meeting
Abatacept Does Not Improve Subclinical Atherosclerosis Despite Good Response in Rheumatoid Arthritis: A Cohort Study
Background/Purpose: Abatacept (ABT) is very effective in treating rheumatoid arthritis(RA)1. Patients with RA have an increased risk of cardiovascular disease (CVD), and rheumatologists need to…Abstract Number: 548 • 2015 ACR/ARHP Annual Meeting
Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
Background/Purpose: The individual response to anti-TNFs etanercept (ETA), infliximab (INF) and adalimumab (ADA) in rheumatoid arthritis (RA) may vary. Options for managing inadequate response include…Abstract Number: 549 • 2015 ACR/ARHP Annual Meeting
Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a protein abundant in cytosol of granulocytes and monocytes/macrophages and released during cell activation. It reflects clinical disease activity in…Abstract Number: 550 • 2015 ACR/ARHP Annual Meeting
Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Background/Purpose: Anti-TNF therapy for RA is associated with antinuclear (ANAs) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.1,2 The effect of biologics on autoantibody-positive patients is unknown. We…
ACR Meeting Abstracts